Patents Represented by Attorney, Agent or Law Firm Karen E. Brown
-
Patent number: 7361665Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable derivative thereof, wherein R1, R2, A, G, and W are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli, Lck, Src, and Aurora kinases. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.Type: GrantFiled: July 9, 2003Date of Patent: April 22, 2008Assignee: Vertex Pharmaceuticals IncorporatedInventors: Mark Ledeboer, Jian Wang, Young Choon Moon
-
Patent number: 7348335Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.Type: GrantFiled: November 5, 2003Date of Patent: March 25, 2008Assignee: Vertex Pharmaceuticals IncorporatedInventors: Randy S. Bethiel, Young-Choon Moon
-
Patent number: 7329652Abstract: The present invention relates to inhibitors of protein kinases, particularly to inhibitors of JAK2 and JAK3. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: September 19, 2005Date of Patent: February 12, 2008Assignee: Vertex Pharamaceuticals IncorporatedInventors: Francesco Salituro, Mark Ledeboer, Brian Ledford, Jian Wang, Albert Pierce, John Duffy, David Messersmith
-
Patent number: 7312227Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.Type: GrantFiled: November 3, 2003Date of Patent: December 25, 2007Assignee: Vertex Pharmaceuticals IncorporatedInventors: Mark Ledeboer, Brian Ledford
-
Patent number: 7271179Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: GrantFiled: May 6, 2003Date of Patent: September 18, 2007Assignee: Vertex Pharmaceuticals IncorporatedInventors: Guy W. Bemis, Scott L. Harbeson, Mark Ledeboer
-
Patent number: 7259161Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.Type: GrantFiled: November 4, 2003Date of Patent: August 21, 2007Assignee: Vertex Pharmaceuticals IncorporatedInventors: Randy S. Bethiel, Mark Ledeboer
-
Patent number: 7226919Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK-3, JAK-3, FLT-3, PIM-1, SYK, or PDK-1 mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.Type: GrantFiled: December 17, 2003Date of Patent: June 5, 2007Assignee: Vertex Pharmaceuticals Inc.Inventors: Mark Ledeboer, Robert Davies, David Messersmith, Young-Choon Moon, Michael Mullican
-
Patent number: 6967075Abstract: This invention provides efficient HCV replicase complexes comprising novel RNA template and primer pair. Assay systems are also provided, which use such complexes, for detecting replicase activity, quantitatively studying the kinetics and mechanism of HCV NS5B-catalyzed nucleotide incorporation, and identifying inhibitors of HCV replicase. The assay systems use small and well-defined synthetic RNAs which allow efficient assembly of all catalytic components in the quaternary complex for HCV NS5B-directed RNA replication. Specific template-primer requirements for efficient RNA synthesis by HCV NS5B replicase are provided for use in assay systems.Type: GrantFiled: April 6, 2001Date of Patent: November 22, 2005Assignee: Schering CorporationInventors: Weidong Zhong, Zhi Hong, Eric Ferrari
-
Patent number: 6559356Abstract: Nucleic acid molecules which encode proteins having fructosyl transferase activity and methods for producing long-chain inulin Nucleic acid molecules are described encoding proteins with the enzymatic activity of a fructosyl transferase. These enzymes are fructosyl transferases (FFT). Moreover, vectors and host cells are described containing the nucleic acid molecules of the invention, in particular transformed plant cells, plant tissue and plants regenerable therefrom, which express the described FFT. Furthermore, methods for the production of long-chain inulin by using the described proteins, hosts, in particular the plant cells and/or FFT produced by them, are described.Type: GrantFiled: May 5, 2000Date of Patent: May 6, 2003Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.VInventors: Arnd G. Heyer, Elke Hellwege, Dominique Gritscher
-
Patent number: 6515203Abstract: Described are nucleic acid molecules encoding enzymes having fructosyl polymerase activity. These enzymes are sucrose dependent sucrose fructosyltransferases (SST) enzymes. Furthermore, vectors and host cells are described containing the nucleic acid molecules, in particular transformed plant cells and plants that can be regenerated from them and that express the described SSTs. Furthermore, methods for the production of short-chain fructosyl polymers using the described hosts and/or the SSTs produced by them are described.Type: GrantFiled: September 3, 1999Date of Patent: February 4, 2003Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Arnd G. Heyer, Elke Hellwege, Dominique Gritscher
-
Patent number: 6468967Abstract: The invention provides methods for administering a therapeutically effective amount of daptomycin while minimizing skeletal muscle toxicity. The methods provide daptomycin administration at a dosing interval of 24 hours or greater. This long dosing interval minimizes skeletal muscle toxicity and allows for higher peak concentrations of daptomycin, which is related to daptomycin's efficacy. The invention also provides methods of administering lipopeptide antibiotics other than daptomycin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity. The invention also provides methods of administering quinupristin/dalfopristin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that does not result in muscle toxicity.Type: GrantFiled: September 24, 1999Date of Patent: October 22, 2002Assignee: Cubist Pharmaceuticals, IncorporatedInventors: Frederick B. Oleson, Jr., Francis P. Tally
-
Patent number: 6455270Abstract: Lichen-derived organic acids such as vulpinic acid and usnic acid have been found to be effective inhibitors of eukaryotic protein kinase activity. Thus, eukaryotic protein kinase activity present in a sample or organism can be inhibited by adding to the sample or organism an effective inhibitory amount of a lichen-derived organic acid.Type: GrantFiled: October 16, 2000Date of Patent: September 24, 2002Assignee: TerraGen Discovery Inc.Inventors: Julian E. Davies, Barbara Waters, Geeta Saxena
-
Patent number: 6441148Abstract: Xylanase DNA is recovered from soil by PCR amplification using degenerate primers. Because of the complexity of the soil samples, it is likely that the recovered product will include more than one species of polynucleotide. These recovered copies may be cloned into a host organism to produce additional copies of each individual species prior to characterization by sequencing. Recovered DNA which is found to vary from known xylanases can be used in several ways to facilitate production of novel xylanases for industrial application. First, the recovered DNA, or probes corresponding to portions thereof, can be used as a probe to screen DNA libraries and recover intact xylanase genes including the unique regions of the recovered DNA. Second, the recovered DNA or polynucleotides corresponding to portions thereof, can be inserted into a known xylanase gene to produce a recombinant xylanase gene with the sequence variations of the recovered DNA.Type: GrantFiled: August 6, 1998Date of Patent: August 27, 2002Assignee: Terragen Diversity, Inc.Inventors: Christopher C. A. Radomski, Kah Tong Seow, R. Antony J. Warren, Wai Ho Yap
-
Patent number: 6245967Abstract: The invention describes recombinant DNA molecules that allow expression of a deregulated or unregulated fructose-1,6-bisphosphatase (FBPase) in plant cells. Such expression leads to an increase in the photosynthesis rate and biomass production in photosynthetically active cells. Furthermore, the invention describes transgenic plants that show an increased photosynthesis rate due to the expression of a deregulated or unregulated FBPase.Type: GrantFiled: September 4, 1997Date of Patent: June 12, 2001Assignee: Hoechst Schering Agrevo GmbHInventors: Uwe Sonnewald, Jens Kossmann, Botho Bowien
-
Patent number: 6225526Abstract: DNA molecules are described which code for a plastid 2-oxoglutarate/malate translocator, particularly from Spinacia oleracea, as well as bacteria, fungi, transgenic plant cells and transgenic plants containing such DNA molecules.Type: GrantFiled: November 12, 1998Date of Patent: May 1, 2001Assignee: BASF AktiengesellschaftInventors: Ulf-Ingo Flügge, Andreas Weber, Karsten Fischer
-
Patent number: 6218142Abstract: Described are nucleic acid molecules encoding polypeptides having the enzymatic activity of an RNA-directed RNA polymerase (RdRP). Vectors comprising said nucleic acid molecules, wherein the nucleic acid molecules are operatively linked to regulatory elements allowing expression in prokaryotic and/or eukaryotic host cells are provided. Additionally, polypeptides encoded by said nucleic acid molecules and methods for the production of said polypeptides are described. Described are also pharmaceutical and diagnostic compositions as well as kits comprising the aforementioned nucleic acid molecules and/or comprising a nucleic acid molecule which is complementary to such a nucleic acid molecule. Said compositions and kits may further comprise polypeptides encoded by the described nucleic acid molecules. Furthermore, antagonists and inhibitors of the aforesaid polypeptides and/or antibodies specifically recognizing such polypeptides are described.Type: GrantFiled: March 5, 1997Date of Patent: April 17, 2001Inventors: Michael Wassenegger, Leonhard Riedel, Winfried Schiebel, Heinz L. Sanger
-
Patent number: 6207880Abstract: Nucleic acid molecules are described encoding a starch granule-bound protein as well as methods and recombinant DNA molecules for the production of transgenic plant cells and plants synthesizing a modified starch with modified viscosity properties and a modified phosphate content. Moreover, the plant cells and plants resulting from those methods as well as the starch obtainable therefrom are described.Type: GrantFiled: March 19, 1998Date of Patent: March 27, 2001Assignee: Planttec Biotechnologie GmbHInventors: Jens Kossmann, Ruth Lorberth